Measuring Protein-Protein Interactions of Melatonin Receptors by Bioluminescence Resonance Energy Transfer (BRET)

Electrically Driven, Bioluminescent Compliant Devices for Soft Robotics

Soft robotics, a research field wherein robots are fabricated from compliant materials, has sparked widespread research interest because of its potential applications in a variety of scenarios. In soft robots, luminescence is an important functionality for communication and information transmission, and it is typically achieved through electroluminescence, which relies on synthetic substances activated by external electric sources, such as batteries. This paper focuses on the use of luciferase, a biologically derived luminescent enzyme, as a luminescent material. Bioluminescence, which is triggered by the luciferin-luciferase reaction, is highly energy-efficient, nontoxic, and eco-friendly. In this regard, a mammalian cell-derived secreted luciferase bioluminescent liquid was developed. This bioluminescent liquid is strongly bright, stable, freezable, and scalable for use as a soft robotic material. To investigate the applicability of this bioluminescent liquid to soft robotics, it was incorporated as an electrode in electrically driven soft actuators, sensors, and robots. Specifically, dielectric elastomer sensors (DESs) and dielectric elastomer actuators (DEAs) were fabricated and characterized using established fabrication processes. The resistivity of the bioluminescent liquid was found to be 448.1 Ω·cm. When the DES was subjected to uniaxial strain, it exhibited a linear response and large deformation of up to 200% strain, with a simultaneous luminance change of 27%. The DEA displayed an areal strain of 46.0% and a luminance change of 31% at an applied voltage of 3.4 kV. The waterproof bending DEA generated a tip angle of 21.8° at 10 kV and was applied to a jellyfish robot that could swim in water at a speed of 2.1 mm/s. The experimental results demonstrated the successful operation of these devices, validating the concept of energy-efficient, safe, and environmentally friendly bioluminescent soft robots.

Melatonin receptor structure and signaling

Melatonin (5-methoxy-N-acetyltryptamine) binds with high affinity and specificity to membrane receptors. Several receptor subtypes exist in different species, of which the mammalian MT1 and MT2 receptors are the best-characterized. They are members of the G protein-coupled receptor superfamily, preferentially coupling to Gi/o proteins but also to other G proteins in a cell-context-depending manner. In this review, experts on melatonin receptors will summarize the current state of the field. We briefly report on the discovery and classification of melatonin receptors, then focus on the molecular structure of human MT1 and MT2 receptors and highlight the importance of molecular simulations to identify new ligands and to understand the structural dynamics of these receptors. We then describe the state-of-the-art of the intracellular signaling pathways activated by melatonin receptors and their complexes. Brief statements on the molecular toolbox available for melatonin receptor studies and future perspectives will round-up this review.

Current advances in the use of bioluminescence assays for drug discovery: an update of the last ten years

INTRODUCTION

Bioluminescence is a well-established optical detection technique widely used in several bioanalytical applications, including high-throughput and high-content screenings. Thanks to advances in synthetic biology techniques and deep learning, a wide portfolio of luciferases is now available with tuned emission wavelengths, kinetics, and high stability. These luciferases can be implemented in the drug discovery and development pipeline, allowing high sensitivity and multiplexing capability.

AREAS COVERED

This review summarizes the latest advancements of bioluminescent systems as toolsets in drug discovery programs for in vitro applications. Particular attention is paid to the most advanced bioluminescence-based technologies for drug screening over the past 10 years (from 2013 to 2023) such as cell-free assays, cell-based assays based on genetically modified cells, bioluminescence resonance energy transfer, and protein complementation assays in 2D and 3D cell models.

EXPERT OPINION

The availability of tuned bioluminescent proteins with improved emission and stability properties is vital for the development of bioluminescence assays for drug discovery, spanning from reporter gene technology to protein-protein techniques. Further studies, combining machine learning with synthetic biology, will be necessary to obtain new tools for sustainable and highly predictive bioluminescent drug discovery platforms.